Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: Long-term follow-up from the American college of surgeons oncology group (Alliance) ACOSOG Z0011 randomized trial

Annals of Surgery

Volumn 264, Issue 3, 2016, Pages 413-419

  Giuliano, Armando E ^a   Ballman, Karla ^b   McCall, Linda ^c   Beitsch, Peter ^d   Whitworth, Pat W ^e   Blumencranz, Peter ^f   Leitch, A Marilyn ^g   Saha, Sukamal ^h   Morrow, Monica ⁱ   Hunt, Kelly K ^j  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c DUKE UNIVERSITY   (United States)

^d Dallas Surgical Group   (United States)

^e Nashville Breast Center   (United States)

^f Morton Plant Hospital   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h MICHIGAN STATE UNIVERSITY   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

ACOSOG Z0011; ALND; Locoregional recurrence; SLND

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ESTROGEN RECEPTOR; TAXANE DERIVATIVE;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE METASTASIS; TUMOR VOLUME; UNITED STATES; AGED; AXILLA; BREAST TUMOR; FOLLOW UP; LYMPH NODE METASTASIS; MIDDLE AGED; PARTIAL MASTECTOMY; PATHOLOGY; PROSPECTIVE STUDY; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SENTINEL LYMPH NODE;

EID: 84983086722     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001863     Document Type: Article

References (23)

1. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569-575.
2. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426-432.
3. Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297-305.
4. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567-575.
5. Anderson WF, Chen BE, Jatoi I, et al. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat. 2006;100:121-126.
6. Jagsi R, Chadha M, Moni J, et al. Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol. 2014;32:3600-3606.
7. Colleoni M, Sun Z, Price KN, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V. J Clin Oncol. 2016;34:927-935.
8. Greco M, Agresti R, Cascinelli N, et al. Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Ann Surg. 2000;232:1-7.
9. Martelli G, Miceli R, Daidone MG, et al. Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Ann Surg Oncol. 2011;18:125-133.
10. Hunt KK, Ballman KV, McCall LM, et al. Factors associated with localregional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg. 2012;256:428-436.
11. Giuliano AE, Hawes D, Ballman KV, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 2011;306:385-393.
12. Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
13. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98:1802-1810.
14. Mannino M, Yarnold JR. Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: can radiotherapy ever be safely withheld? Radiother Oncol. 2009;90:14-22.
15. Morrow M. Rethinking the local therapy of breast cancer: integration of biology and anatomy. Ann Surg Oncol. 2015;22:3168-3173.
16. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302-2313.
17. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29-36.
18. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595-600.
19. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinellymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881-888.
20. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599-609.
21. Zavagno G, De Salvo GL, Scalco G, et al. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247:207-213.
22. Houvenaeghel G, Classe JM, Garbay JR, et al. Survival impact and predictive factors of axillary recurrence after sentinel biopsy. Eur J Cancer. 2016;58: 73-82.
23. Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for nodepositive breast cancer. J Clin Oncol. 2009;27:2946-2953.